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One hundred years have passed since Archibald Garrod postulated the one gene/one enzyme
hypothesis. Since then, science has made signiﬁcant progress and geneticists are now tackling an
overwhelming complexity of gene regulation networks that underlie the genetics of complex
human diseases. A particularly complex element in the biology of higher organisms is the
genetics of protein glycosylation. Nearly all proteins that appeared after the emergence of
multicellular life are glycosylated, but instead of being molded by a single gene, glycan structures
are encoded within a network of several hundred glycosyltransferases, glycosidases, transporters,
transcription factors and other proteins. In addition, in contrast to the linear structures of DNA
and proteins, glycans have multiple branches that make their analysis signiﬁcantly more
challenging. However, recent developments in high throughput HPLC analysis have advanced
glycan analysis signiﬁcantly and it is now possible to address questions about the complex
genetics of protein glycosylation. In this review we present some preliminary insights into this
fascinating ﬁeld.
1. Structural and functional aspects of protein
glycosylation
Carbohydrates have been a focus of human interest since the very
beginning of civilization, but we have only recently started to
understand the importance of complex oligosaccharides (glycans)
attached to protein or lipid backbones. This is perhaps not
surprising, since the branched structures of sugars make the
analysis of glycoconjugates signiﬁcantly more challenging than
the analysis of linear DNA and protein sequences.
Glycosylation is the only post-translational modiﬁcation
that can produce signiﬁcant structural changes to proteins.
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A typical glycan is a complex molecule containing between 10
and 15 monosaccharides linked in a rather complicated
manner. Between two and ﬁve glycans are attached to an
average glycoprotein, resulting in an exceedingly complex
glycoproteome, estimated to be several orders of magnitude
more complex than the proteome itself.1
In eukaryotes, glycosylation occurs through 11 biosynthetic
pathways.2 The oldest pathway, which is ubiquitously present,
is N-glycosylation. This occurs when a block of 14 sugars (the
dolichol phosphate precursor) is transferred co-translationally
to speciﬁc asparagine (Asn) residues in newly synthesized
polypeptides in the endoplasmic reticulum.3 The resulting
N-glycans are subjected to extensive modiﬁcation as glyco-
proteins mature and move via the Golgi complex to their
intra- and extra-cellular destinations.4
Depending on the structure of a glycan and the protein
to which it is attached, glycans can have many diﬀerent
functions: they can be important in the proper folding of
proteins; they can regulate the function of protein backbones
by diﬀerential processing of glycosylation;5 they can be
strategically placed so that they are able to provide protease
protection without interfering with the function of the protein;
they can serve as recognition motifs for speciﬁc carbohydrate
binding proteins (lectins) and mediate cell–cell interactions;6
they can enable proteins and lipids to ‘‘jump’’ from one cell to
another;7 and they can also have many other functions, some
of which are still poorly understood.8
The complex shape, functionality and dynamic properties of
glycans allow these molecules to function in intermolecular
interactions as encoders of biological information. Carbo-
hydrate recognition is an integral part of normal biological
development9 and the immune defence against pathogens is
mediated through the identiﬁcation of exogenous carbo-
hydrates.10 Cells of higher eukaryotes are covered with a dense
layer of glycoconjugates (glycocalyx) which are responsible for
their communication with the outside world. Many bacterial
and viral pathogens initially adhere to host tissues by binding
speciﬁcally to carbohydrates on the host cell surfaces,11 thus
the heterogeneity of glycan structures represents a valuable
tool that higher eukaryotes use to outmanoeuvre rapidly
evolving pathogens. Evolutionary processes have employed
the potential for variability oﬀered by glycosylation and have
resulted in the enormous complexity in glycan structures that
we observe today in multicellular organisms. The transition
from a single cell to multicellular organisms required the
invention of many new molecules and mechanisms, needed
to guide and control interactions between individual cells and
their surroundings including other cells, the extracellular
matrix, and pathogens. Glycosylation was apparently a very
useful tool in this evolutionary process, and today, nearly all
membrane and extracellular proteins are glycosylated.12
Even though the mass content of glycans in a glycoprotein is
often rather small (5–10%), since glycans have a much lower
density than proteins, glycans always represent a signiﬁcant
part of the hydrodynamic volume of the glycoprotein. In spite
of diﬀerences in genealogy and biosynthetic mechanisms of the
carbohydrate and protein entities that constitute a glyco-
protein, once synthesized, the glycoprotein functions as a
single unit and other interacting molecules cannot diﬀerentiate
whether they are binding to a protein, or a carbohydrate part
of the molecule.13 Structural and conformational aspects of
glycans are very complex,14 and a small change in a glycan
structure can have important functional consequences.
Therefore, in order to comprehend the functions of glyco-
conjugates, it is necessary to determine the structure and
function of their glycans. For example, it is diﬃcult to imagine
that the function of the prion protein (Fig. 1) could be fully
explained without understanding its glycan part.
N-glycosylation is essential for multicellular life and its
complete absence is embryonically lethal.15 Genetic defects
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that aﬀect protein glycosylation are relevant to human health
and cause a number of diﬀerent human diseases.16,17 In
addition, it has been shown that a surprisingly high share of
all known disease-causing missense mutations result in gains
of potential glycosylation sites.18,19 Contrary to core glycans,
which appear to be essential for the functions of many
glycoproteins, variability in monosaccharides at the end of
glycan antennas is common (e.g., ABO blood groups). This
structural diversity of glycans contributes to glycoprotein
heterogeneity in a population that can be advantageous for
evading pathogens and adapting to changing environment.8
One example of a protein where structural and functional
aspects of glycosylation have been studied in detail is the
immunoglobulin G (IgG) molecule. Glycan structures
attached to the Asn297 residue in the constant (CH2) domains
of IgG are critical for maintaining the overall structure and
function of the molecule.20 For over 20 years, it has been
known that a decrease in the number of galactose residues at
the non-reducing termini of these glycans is associated with
various diseases.20–22 Under-galactosylation in rheumatoid
arthritis apparently precedes the outbreak of other symptoms,
and, when clustered, agalactosyl glycoforms may initiate the
complementary pathway, thus contributing to the patho-
genesis of the disease.23 IgG mediates both pro- and anti-
inﬂammatory activities through the engagement of its Fc
fragment with distinct receptors. These distinct properties
of the IgG Fc result from diﬀerential glycosylation.24 IgG
acquires anti-inﬂammatory properties upon Fc sialylation,
which is reduced upon the induction of an antigen-speciﬁc
immune response. This diﬀerential sialylation may provide a
switch from innate anti-inﬂammatory activity in the steady
state to generating adaptive pro-inﬂammatory eﬀects upon
antigenic challenge.25 Glycosylation of IgG also plays an
important role in mediating antibody-dependent cellular
cytotoxicity (ADCC) following treatment with therapeutic
antibodies, and this is closely related to the clinical eﬃcacy
of anticancer drugs. The lack of core fucose in glycans
Fig. 1 Prion protein (PrPC). Prion protein is a glycoprotein composed
of the amino acid backbone (green), two N-glycans at Asn 181 (light
blue) and Asn 197 (dark blue), and a glycosylphosphatidylinositol
anchor (orange). The N-glycans are modeled to show the range of
conformational space available to the sugars. Figure courtesy of M. R.
Wormald, R. A. Dwek and P. M. Rudd, Glycobiology Institute,
Oxford, UK.
Fig. 2 Platform for robotics-compatible high-throughput HPLC-based method for glycan analysis with computer-assisted data interpretation
(Dublin-Oxford Group, NIBRT, Ireland).















































attached to the Fc region of antibodies improves Fc gamma
RIIIa binding, allowing the antibodies to enhance dramatically
the antibody eﬀector functions of ADCC.26
2. Variability and heritability of glycans
Glycans display a much higher variability between species
than proteins,27–29 indicating that they evolve much more
rapidly. Until recently, due to the technological challenges,
detailed quantitative analysis of total plasma glycans was
generally performed on a limited number of samples;30 thus,
insights into glycome variability at the population level
are very limited. Using a newly developed 96-well plate
high-performance liquid chromatography platform (Fig. 2),31
we have demonstrated that human plasma N-glycans can be
separated into chromatographic peaks and quantiﬁed reliably
in a relatively high-throughput manner.32 This represents a
major technological advance, one which was required to
investigate the genetic regulation and biological role of glycan
structures and to bring glycomics into line with genomics,
proteomics and metabolomics.33 Other methods that enable
high-throughput glycan analysis, like mass spectrometry (MS)
or capillary electrophoresis (CE), were until now not shown to
be adequate for this type of study. The main problem in MS
analysis of glycans is the limited ability to reliably quantify
diverse glycan structures, while capillary electrophoresis lacks
suﬃcient resolution to analyze complex mixtures.
By analyzing the distribution of plasma glycans in a sample
of 1008 individuals, we observed an unusually large biological
variability at the population level, with a median ratio of
minimal to maximal values of 6.2. Due to experimental
limitations, in that study we did not quantify individual glycan
structures, but instead measured glycans partitioned into 33
groups containing several (mostly similar) glycan structures.32
Despite the fact that diﬀerent glycans within the same group
could have changed in opposite directions, thus diminishing
the cumulative change, the variability of glycans in the
population was found to be high. This apparently large
variability of glycan structures should not be ignored in
the development of diagnostic tools based on measuring
alterations in glycan levels, since the magnitude of reported
changes associated with a disease30,34–37 is sometimes smaller
than the observed natural variability revealed in this study.
However, it should be noted that this study only compared
ratios of plasma glycans grouped into 33 chromatographic
peaks and the possible presence or absence of some less
abundant structures in speciﬁc individuals was not examined.
Variations observed in a human phenotype are generally
due to the joint inﬂuence of genetic diﬀerences and varying
exposures to environmental factors. Heritability is one of the
most basic and often one of the ﬁrst analyses made in a genetic
study. Since it represents the proportion of the trait variance
that can be attributed to genetic factors, it is often used as a
ﬁrst screening tool to assess whether a trait may be suitable for
gene mapping.38 In our recent study, we performed the ﬁrst
estimation of heritability for a range of diﬀerent N-glycans. A
broad range of variation in heritability was observed, from
insigniﬁcant or very low to high, indicating that while some
glycans are mostly controlled by genetic factors, others are
mainly under environmental control. Heritability is important
since it can provide information about the underlying
genetic structure of the trait, by reporting on additive
and dominant variance components.39,40 However, the
interpretation of heritability estimates is complicated by
a number of factors.38 Diﬀerences in methodological
approaches and sampling schemes, variation in trait values
over time, and population-speciﬁc diﬀerences can all inﬂuence
heritability values,38 resulting in a wide range of heritability
estimates in diﬀerent studies. The latter is largely due to
the fact that since heritability is (in the simplest form)
calculated as the ratio of genetic over genetic and environ-
mental variance, its estimation depends on the environment
from which the sample has been collected. Care should
therefore be taken in comparing heritability estimates from
diﬀerent populations.
Age, gender and age–gender interaction eﬀects were found
to be statistically signiﬁcant in the majority of the glycan
groups, although their eﬀect was relatively small, generally
in the range of up to 10%.32 A number of environmental
variables (such as smoking) were also found to be associated
with plasma glycome components in a very complex manner.
These variables should ideally be measured and included in
the analysis of future studies investigating the relationship
between plasma glycan levels and disease or disease traits.
3. Advances in genetic investigation of common
complex diseases and disease traits
Until about three years ago, genetic linkage studies using
scarce sets of genetic markers and candidate-gene approaches
based on a priori hypotheses on biological plausibility were
the major designs used to study the role of human genetic
variation in common complex diseases of late onset. However,
the linkage approach has only been successful in identifying
rare genetic mutations with high penetrance and large eﬀects
in extended pedigrees aﬀected by monogenic (‘‘Mendelian’’)
disorders. These studies were grossly underpowered to detect
more common genetic variants of smaller eﬀect sizes in the
samples drafted from general population.41 The candidate
gene studies have typically used sample sizes of several
hundred cases and controls and the vast majority of reported
positive results over the past decade have never been replicated
in subsequent studies.42,43
More recently, however, a major technological break-
through occurred. Advances in genotyping technologies were
combined with the results of the HapMap project, which
identiﬁed and validated more than 3 million of the new class
of genetic markers—‘‘single nucleotide polymorphysms’’
(SNPs). The selection (‘‘haplotype tagging’’) of several
hundred thousand of a particularly useful subset of these
SNP markers was then performed, taking into account
recombination hotspots in the genome and their linkage
disequilibrium (LD) patterns. This has resulted in the
development of high density SNP arrays with hundreds of
thousands of SNP markers spanning across the entire genome,
which made hypothesis-free genome-wide association studies
(GWAS) possible.44















































In parallel with these advances, appropriate statistical and
computational methods were developed to deal with issues
such as population stratiﬁcation, relatedness of the subjects in
the sample and multiple testing, with agreement on a
very stringent genome-wide statistical signiﬁcance level of
approximately p = 5  10E-7 when a set of about 300 000
SNPs is used, to avoid false-positive results that plagued the
ﬁeld for more than a decade.45,46 These were conducted
initially as separate studies in reasonably small sample sizes
of up to 2000 cases and controls, but initial successes soon
resulted in the formation of very large consortia and pooling
of the samples among several studies in genome-wide association
study meta-analyses. Current sample sizes of the largest
consortia, such as GIANT (which studies anthropometric
traits) or DIAGRAM (which studies type 2 diabetes), reach
about a hundred thousand cases and controls. Hundreds of
common genetic variants underlying complex human diseases
and biomedically relevant quantitative traits have been
identiﬁed, and widely replicated across populations. Genetic
networks inﬂuencing a wide range of common complex
diseases have begun to emerge, including type 1 and 2 diabetes,
ischaemic heart disease, stroke, rheumatoid arthritis, breast/
prostate/colorectal/lung cancer and inﬂammatory bowel
disease, and a range of endophenotypes underlying these
diseases, such as obesity, LDL cholesterol and fasting glucose.
These variants typically had small eﬀect sizes (ORs of 1.1–1.4)
and many have been located in regions outside the known
genes, presumably in distant regulatory regions. These
variants individually only explain a very small percentage of
the overall variance in disease or traits and thus cannot be
used at this point in time for a reliable genetic proﬁling
of disease risk in individual subjects. However, many new
aetiological hypotheses have been generated and these GWAS
have formed a robust base of new knowledge on which
functional studies can now build to explore new disease
pathways.47–49 This should all eventually result in improved
prediction of disease risk and a highly personalized era of
medicine with new class of drugs that will exploit the new
knowledge generated by these studies.
4. Complex genetics of protein glycosylation
Glycosylation is the most diverse post-translational protein
modiﬁcation. Hundreds of speciﬁc enzymes and other proteins
are involved in the synthesis of complex glycans that are
covalently bound to protein backbones.50 Some of these
enzymes are very speciﬁc and contribute to the synthesis of a
limited number of structures on a small number of proteins,51
while others (like ER-glycosyltransferases involved in synthesis
of N-glycans, or pathways that produce sugar nucleotides)
aﬀect thousands of diﬀerent proteins. This process is not
template driven and is thus prone to the inﬂuence of various
diﬀerent internal and external factors. The intricate mechanisms
by which the interplay of gene expression and intracellular
localization of their products give rise to speciﬁc glycan
structures is only starting to be understood.52
Contrary to the polypeptide backbone, glycan parts of
glycoproteins are not directly encoded in genes. Instead of
being moulded by a single gene, glycan structures are encoded
in a network of hundreds of glycosyltransferases, glycosidases,
transporters, transcription factors and other proteins. The
invention of glycosylation represented a signiﬁcant evolutionary
advantage since it can produce novel structures by modifying
gene expression, intracellular localization and activity of
biosynthetic enzymes. This invention occurred in parallel with
the appearance of multicellular life, and even though it is
too speculative to claim that the invention of glycosylation
enabled the appearance of multicellular life, the fact that
nearly all proteins that came into existence after the appearance
of multicellular organisms are glycosylated, indicates the
importance of glycosylation for complex organisms.
Due to technological limitations in studying branched
chains of glycans, the knowledge about genes and genetic
polymorphisms that regulate glycosylation is mostly limited
to a small number of glycosyltransferases that directly synthesize
glycans.16 The number of functional polymorphisms in these
genes appears to be limited since each change in them aﬀect
thousands of proteins and have important consequences for
survival.16 In addition to glycosyltransferases, numerous other
proteins like transcription factors, transporters and Golgi
organizers are involved in protein glycosylation. The use of
these proteins frequently varies between diﬀerent cell types
and physiological states; thus, mutations in their genes
would not be as deleterious at the level of the organism.
Consequently, it is likely that polymorphisms in these genes
might be even more important for determining variations in
levels of individual glycan structures in human populations,
than polymorphisms in genes for glycosyltransferases.
The recent technological advances in both human genomics
and glycomics analysis described above have now made
it possible to bring together high throughput genomics and
high-throughput glycomics and to apply the successful design
of genome-wide association studies to investigate genetic
regulation of the human glycome. After demonstrating that
glycan measurements were reproducible and that plasma
N-glycan levels are heritable,32 we recently attempted the ﬁrst
genome-wide association study of human plasma N-glycan
levels using the Illumina Human Hap300 platform (comprising
317 503 SNP). These studies are still in progress and the results
need to be replicated, but they appear to be very successful. As
a proof of principle that glycans measured by HPLC are
amenable to genome-wide association studies, we recently
reported the identiﬁcation of polymorphisms that aﬀect levels
of the A2 glycan (GlcNAc2Man3GlcNAc2) in human plasma
proteins.53 The most signiﬁcant association was found with a
single nucleotide polymorphism rs7161123 located in intron 2
of the gene fucosyltransferase 8 (Fig. 3). Allele A of this SNP
alone explained 3.93% of the variance of glycan A2 (after
adjustment for age and sex).
5. Conclusions and future prospects
The past few years have witnessed an exponential increase in
the level of knowledge about the importance of glycans in
numerous physiological and patho-physiological processes.
The recent development of new robust high-throughput
methods that enable reliable quantitative analysis of numerous
samples paved the way for high-throughput glycomics to join















































high-throughput genomics and proteomics on the forefront of
modern science—the ‘‘multi-dimensional biology’’. The
analysis of both genetic polymorphisms and glycan levels in
the same individuals will enable insights into complex systems
of diﬀerent transcription factors, transporters, enzymes,
quality control chaperones and other proteins that regulate
protein glycosylation. Determining the genetic polymorphisms
in genes that code for these proteins will enable us to
better understand molecular processes that underlay many
diseases and provide a whole new set of targets for future
pharmacological interventions.
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